MK-677 vs GHRP-6

Side-by-side comparison of MK-677, GHRP-6 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute MK-677 MK-677 (Ibutamoren) — Oral GH Secretagogue Growth Hormone GHRP-6 Growth Hormone Releasing Peptide-6 Growth Hormone
Basics
Molecular type Non-Peptide GH SecretagogueGrowth Hormone Releasing Peptide (GHRP)
Amino acids —6
Molecular weight 624.8 Da873.0 Da
Half-life ~24 hours~15–60 min
Route(s) OralSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism MK-677 mimics ghrelin's binding to GHSR-1a receptors, activating the same signalling cascade that endogenous ghrelin uses to stimulate GH release. As a small non-peptide molecule, it resists enzymatic degradation and is … GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining …
Research status Research Compound Research Compound
Evidence summary MK-677 has one of the most extensive clinical datasets of any non-approved GH secretagogue, with Phase 1/2 trials across multiple populations including GH-deficient adults, elderly frail patients, and post-hip-fracture p… GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmac…
Protocol & Dosing
Typical dose 10–25 mg/day100–300 mcg per injection
Frequency Once daily2–3× daily
Duration 8–16 weeks; some protocols run 6 months8–12 weeks
Timing Bedtime (maximises nocturnal GH pulse; also reduces daytime appetite impact)Fasted state or 2+ hours post-meal
Safety
Common side effects
  • Increased appetite (often significant)
  • Water retention / oedema
  • Tingling or numbness (extremities)
  • Fatigue (initial weeks)
  • Significant appetite increase (most common)
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Water retention
Contraindications
  • Active malignancy
  • Uncontrolled diabetes (insulin resistance worsening)
  • Severe fluid retention conditions (CHF, severe liver disease)
  • Active malignancy
  • Eating disorders (appetite amplification concern)
  • Hypothyroidism
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, CJC-1295, GHRP-6 Ipamorelin, GHRP-2, Hexarelin, CJC-1295
Full profile Read full MK-677 profile → Read full GHRP-6 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.